Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 1815 |
| INN | Rilotumumab |
| Status | Terminated |
| Drug code(s) | AMG 102 |
| Brand name | None |
| mAb sequence source | mAb human |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG2 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | Transgenic mouse (Xenomouse)-derived |
| Target(s) | HGF |
| Indications of clinical studies | Glioma, Glioblastoma Multiforme, Non-Small-Cell Lung cancer, Renal Cell Carcinoma, Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Small Cell Lung Cancer, Colorectal Cancer |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Terminated at Phase 3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | December 16, 2004 |
| Start of Phase 2 | November 15, 2006 |
| Start of Phase 3 | October 15, 2012 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Amgen |
| Licensee/Partner | None |
| Comments about company or candidate | Amgen has discontinued development of rilotumumab, a fully-human MAb that inhibits hepatocyte growth/scatter factor and c-met, for the treatment of cancer, following a safety review by the RILOMET-1 independent data monitoring committee found an increase in the number of deaths in the rilotumumab and chemotherapy treatment arm when compared to the chemotherapy treatment only arm Phase 1/2 with Amgen as collaborator ongoing as of Feb 2016. Partnership with Astellas for marketing in Japan. Failed in Phase 3 in gastric cancer |
| Full address of company | Thousand Oaks, California, United States North America United States of America https://www.amgen.com/ |
Oct 2007 publication: AMG 102, a fully human monoclonal antibody that binds to hepatocyte growth factor (HGF), is a potential cancer therapeutic agent because of its ability to disrupt HGF/c-Met signaling pathways which have been implicated in most tumor types. To support a phase 1 study, the pharmacokinetic and safety profile of AMG 102 was assessed in cynomolgus monkeys. https://pubmed.ncbi.nlm.nih.gov/17520181/
| Anticipated events | None |
| Factor(s) contributing to discontinuation | Safety |